JP2024546201A - サルブタモールを含む医薬組成物 - Google Patents

サルブタモールを含む医薬組成物 Download PDF

Info

Publication number
JP2024546201A
JP2024546201A JP2024533818A JP2024533818A JP2024546201A JP 2024546201 A JP2024546201 A JP 2024546201A JP 2024533818 A JP2024533818 A JP 2024533818A JP 2024533818 A JP2024533818 A JP 2024533818A JP 2024546201 A JP2024546201 A JP 2024546201A
Authority
JP
Japan
Prior art keywords
mass
pharmaceutical composition
salbutamol
active ingredient
canister
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546201A5 (enExample
Inventor
ペイロン，イサベル
ロッシ，イレーネ
サライユ，セゴレーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptar France SAS
Original Assignee
Aptar France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptar France SAS filed Critical Aptar France SAS
Publication of JP2024546201A publication Critical patent/JP2024546201A/ja
Publication of JP2024546201A5 publication Critical patent/JP2024546201A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024533818A 2021-12-20 2022-12-19 サルブタモールを含む医薬組成物 Pending JP2024546201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2113999A FR3130554B1 (fr) 2021-12-20 2021-12-20 Composition pharmaceutique comprenant du salbutamol
FR2113999 2021-12-20
PCT/FR2022/052421 WO2023118717A1 (fr) 2021-12-20 2022-12-19 Composition pharmaceutique comprenant du salbutamol

Publications (2)

Publication Number Publication Date
JP2024546201A true JP2024546201A (ja) 2024-12-18
JP2024546201A5 JP2024546201A5 (enExample) 2025-12-04

Family

ID=80595325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533818A Pending JP2024546201A (ja) 2021-12-20 2022-12-19 サルブタモールを含む医薬組成物

Country Status (9)

Country Link
US (1) US20250041244A1 (enExample)
EP (1) EP4452227B1 (enExample)
JP (1) JP2024546201A (enExample)
CN (1) CN118510492A (enExample)
AU (1) AU2022420913A1 (enExample)
CA (1) CA3238932A1 (enExample)
FR (1) FR3130554B1 (enExample)
MX (1) MX2024006942A (enExample)
WO (1) WO2023118717A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250281404A1 (en) * 2024-03-07 2025-09-11 Recipharm Laboratories, Inc. Composition for use in pressurised dispensing container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020204A2 (en) * 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition

Also Published As

Publication number Publication date
MX2024006942A (es) 2024-09-10
FR3130554A1 (fr) 2023-06-23
CN118510492A (zh) 2024-08-16
WO2023118717A1 (fr) 2023-06-29
CA3238932A1 (fr) 2023-06-29
AU2022420913A1 (en) 2024-05-23
FR3130554B1 (fr) 2024-10-18
EP4452227B1 (fr) 2025-11-26
EP4452227A1 (fr) 2024-10-30
US20250041244A1 (en) 2025-02-06
EP4452227C0 (fr) 2025-11-26

Similar Documents

Publication Publication Date Title
AU2003222753B2 (en) Formoterol superfine formulation
WO2004019985A1 (en) Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
HUP0200083A2 (en) Pharmaceutical composition containing combinations of formoterol and a tiotropium salt and their use
JP2010539182A (ja) 治療剤の新規組み合わせ
WO2014016548A2 (en) Pharmaceutical composition
CN102905694B (zh) 吸入溶液
KR101668203B1 (ko) 천식의 병세악화를 예방 및/또는 치료하기 위한 포르모테롤 및 베클로메타손 디프로피오네이트를 포함하는 조성의 용도
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
JP7828949B2 (ja) 吸入投与のための併用療法
JP2004515454A (ja) 気管支肺疾患の治療のためのグルココルチコイド薬物を含有する製剤
US20130104881A1 (en) Stabilized Metered Dose Inhaler
US20250041244A1 (en) Pharmaceutical composition comprising salbutamol
JP2025522005A (ja) サルブタモールを含む医薬組成物
AU2013246692A1 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
JP7838011B2 (ja) 加圧分配容器における使用のための組成物
JP2007528889A (ja) 吸入製剤
HK1176290B (en) Inhalation solutions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240731

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251126